Bristol-Myers Squibb has raised its dividend for 15 consecutive years, a record that reflects stable cash generation from a portfolio of blockbuster drugs. The company faces a familiar challenge in the pharmaceutical industry: patent expirations on major revenue drivers while newer therapies ramp toward commercial scale. Income investors are watching whether the dividend can continue growing through this transition.
The setup
Bristol-Myers Squibb generates revenue from oncology, immunology, and cardiovascular franchises. Key products include Eliquis for anticoagulation, Opdivo for multiple cancers, and Revlimid for multiple myeloma. Revlimid now faces generic competition following patent expiry, creating a revenue headwind the company must offset.
The pipeline includes newer assets in cell therapy and protein degradation. Commercial execution on these programs will determine whether revenue stabilizes in the mid-2020s.
Key numbers
| Metric | Value | Context |
|---|---|---|
| Annual dividend per share | $2.40 | Quarterly rate of $0.60 |
| Current yield | 4.8% | Based on recent trading near $50 |
| Consecutive years of increases | 15 | Through 2025 |
| Payout ratio | 67% | Elevated due to patent cliff pressures |
| R&D spending (annual) | $11.2 billion | Approximately 25% of revenue |
A $100,000 position in Bristol-Myers Squibb stock at current yields would produce approximately $4,800 in annual dividend income. This exceeds the income from most consumer staples and technology dividend payers.
Per $100K comparison
| Stock | Ticker | Annual Dividend per $100K |
|---|---|---|
| Bristol-Myers Squibb | BMY | ~$4,800 |
| Pfizer | PFE | ~$5,800 |
| Merck | MRK | ~$3,100 |
| AbbVie | ABBV | ~$3,500 |
Bristol-Myers Squibb sits between Pfizer’s higher yield and Merck’s lower payout. AbbVie offers a middle ground with a stronger near-term growth profile from Skyrizi and Rinvoq.
What to watch
Pipeline execution is the critical variable. The company needs new products to reach peak sales before legacy revenue declines accelerate. Analysts at Mizuho Securities have flagged the 2026-2028 period as decisive for the company’s revenue trajectory.
Debt levels also matter. Bristol-Myers Squibb carried approximately $37 billion in long-term debt following its 2019 Celgene acquisition. Management has prioritized debt reduction while maintaining the dividend. Investors should monitor whether balance sheet repair slows if pipeline setbacks occur.
Regulatory approval timing for late-stage candidates can swing sentiment rapidly. Any delay in a key filing could pressure the stock and raise questions about dividend sustainability.
Common mistakes income investors make
Some investors select pharmaceutical stocks based solely on yield without examining pipeline depth. A 4.8 percent yield is attractive only if the underlying business can fund it. Patent cliffs can erode cash flows faster than dividends adjust.
Others fail to diversify across therapeutic areas. Concentrating in one pharmaceutical name exposes income to clinical trial failures and regulatory setbacks. A basket approach across oncology, immunology, and cardiovascular franchises reduces single-product risk.
Analyst outlook for Bristol-Myers Squibb
Analysts at Goldman Sachs maintain a “Neutral” rating on Bristol-Myers Squibb with a price target of $55. They acknowledge the yield appeal but flag near-term earnings pressure from Revlimid erosion. BMO Capital Markets assigns an “Outperform” rating with a fair value of $62, citing pipeline optionality in cell therapy.
Morgan Stanley analysts note that the company’s ability to reduce its debt burden while maintaining dividend growth will be a key signal for income investors. They expect debt ratios to improve gradually through 2027 if pipeline milestones are met.
The consensus view among surveyed firms suggests the stock is fairly valued for income-oriented holders but carries above-average clinical risk compared to peers like Merck and Johnson & Johnson.
Bottom line
Bristol-Myers Squibb offers one of the higher yields in large-cap pharmaceuticals. The 15-year dividend growth streak supports its credibility with income investors. The key question is whether pipeline revenues can replace lost patent protection before the payout ratio becomes unsustainable. Conservative investors may consider a modest position while monitoring clinical trial readouts.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
